Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Panel Votes Yes on Cancer Drug

By Drug Discovery Trends Editor | September 3, 2009

WASHINGTON (AP) – Federal health experts voted Wednesday in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer.

A spokeswoman for the Food and Drug Administration said the agency’s panel of oncology experts voted 10-4 that the company’s drug pralatrexate would likely benefit patients with T-Cell lymphoma.

The FDA is not required to follow the group’s advice, though it often does.

T-cell lymphoma is a type of cancer that attacks the immune system. There are currently no FDA approved treatments for the disease. Westminister, Colo.-based Allos has asked the FDA to approve its drug for patients whose cancer reoccurs or has not responded to other drugs.

Company studies of the drug showed 27 percent of patients with T-Cell lymphoma responded to treatment, with more than half responding for about three months.

Panelists said the results suggest the drug could increase overall survival for T-cell Lymphoma patients, adding that new treatments are needed for the disease.

The FDA is scheduled to make a decision on the drug by Sept. 24.

“We are very pleased that the advisory committee today voted to recommend accelerated approval of the Folotyn NDA,” said Paul L. Berns, CEO at Allos Therapeutics, in a statement. “We believe Folotyn has the potential to offer an important new treatment option for patients with relapsed or refractory PTCL, an indication for which there are currently no FDA-approved therapies and no accepted standard of care.”

Shares of Allos closed unchanged Wednesday at $7.86.

Date: September 3, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE